» Articles » PMID: 26459038

Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2015 Oct 14
PMID 26459038
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Due to the high recurrence risk of nonmuscle invasive urothelial carcinoma it is crucial to distinguish patients at high risk from those with indolent disease. In this study we used a machine learning algorithm to identify the genes in patients with nonmuscle invasive urothelial carcinoma at initial presentation that were most predictive of recurrence. We used the genes in a molecular signature to predict recurrence risk within 5 years after transurethral resection of bladder tumor.

Materials And Methods: Whole genome profiling was performed on 112 frozen nonmuscle invasive urothelial carcinoma specimens obtained at first presentation on Human WG-6 BeadChips (Illumina®). A genetic programming algorithm was applied to evolve classifier mathematical models for outcome prediction. Cross-validation based resampling and gene use frequencies were used to identify the most prognostic genes, which were combined into rules used in a voting algorithm to predict the sample target class. Key genes were validated by quantitative polymerase chain reaction.

Results: The classifier set included 21 genes that predicted recurrence. Quantitative polymerase chain reaction was done for these genes in a subset of 100 patients. A 5-gene combined rule incorporating a voting algorithm yielded 77% sensitivity and 85% specificity to predict recurrence in the training set, and 69% and 62%, respectively, in the test set. A singular 3-gene rule was constructed that predicted recurrence with 80% sensitivity and 90% specificity in the training set, and 71% and 67%, respectively, in the test set.

Conclusions: Using primary nonmuscle invasive urothelial carcinoma from initial occurrences genetic programming identified transcripts in reproducible fashion, which were predictive of recurrence. These findings could potentially impact nonmuscle invasive urothelial carcinoma management.

Citing Articles

Artificial intelligence application in the diagnosis and treatment of bladder cancer: advance, challenges, and opportunities.

Ma X, Zhang Q, He L, Liu X, Xiao Y, Hu J Front Oncol. 2024; 14:1487676.

PMID: 39575423 PMC: 11578829. DOI: 10.3389/fonc.2024.1487676.


The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century.

Varnosfaderani S, Forouzanfar M Bioengineering (Basel). 2024; 11(4).

PMID: 38671759 PMC: 11047988. DOI: 10.3390/bioengineering11040337.


A hybrid particle swarm optimization algorithm for solving engineering problem.

Qiao J, Wang G, Yang Z, Luo X, Chen J, Li K Sci Rep. 2024; 14(1):8357.

PMID: 38594511 PMC: 11375002. DOI: 10.1038/s41598-024-59034-2.


expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.

Kim K, Byun Y, Zheng C, Moon S, Jo S, Kang H Investig Clin Urol. 2024; 65(1):94-103.

PMID: 38197756 PMC: 10789541. DOI: 10.4111/icu.20230227.


Artificial Intelligence in Urooncology: What We Have and What We Expect.

Fron A, Semianiuk A, Lazuk U, Ptaszkowski K, Siennicka A, Leminski A Cancers (Basel). 2023; 15(17).

PMID: 37686558 PMC: 10486651. DOI: 10.3390/cancers15174282.